Gufic Biosciences Q2 Results FY27: Net Profit Rises 39.54% YoY, Revenue Rs 288.27 Cr, PAT Rs 23.47 Cr
- November 14, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Gufic Biosciences Q2 Results FY27 were declared on 14 November 2026 for the July to September 2026 quarter on a Consolidated basis. Revenue rose 21.61% YoY to Rs 288.27 Cr from Rs 237.05 Cr, and net profit (PAT) rose 39.54% to Rs 23.47 Cr from Rs 16.82 Cr. These quarterly results show positive YoY growth in all three lines, with Operating Profit up 28.11% to Rs 48.49 Cr.
Gufic Biosciences Ltd (GUFICBIO) Q2 Results FY27 announced on 14 November 2026, covering the company’s financial performance for the July to September quarter. The results date marks the filing, and the consolidated results show revenue of Rs 288.27 Cr and PAT of Rs 23.47 Cr. Gufic Biosciences Q2 Results FY27 therefore pair a 21.61% revenue rise with a 39.54% rise in net profit.
This Univest note on Gufic Biosciences Q2 Results covers the financial highlights, business drivers, outlook and risks. The results analysis starts from the Financial Highlights table below, which sets each figure beside the same quarter a year ago.
Click Here – Get Free Investment Predictions
Gufic Biosciences Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 288.27 Cr | Rs 237.05 Cr | +21.61% YoY |
| Operating Profit | Rs 48.49 Cr | Rs 37.85 Cr | +28.11% YoY |
| Net Profit (PAT) | Rs 23.47 Cr | Rs 16.82 Cr | +39.54% YoY |
Source: company filing for Gufic Biosciences Q2 Results FY27, 14 November 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Gufic Biosciences Q2 Results: What Stands Out
- Revenue Rs 288.27 Cr: sales rose 21.61% from Rs 237.05 Cr in the year-ago quarter, the smallest YoY change among the three headline lines.
- Net profit Rs 23.47 Cr: PAT rose 39.54% from Rs 16.82 Cr, the steepest YoY change among the three lines.
- Operating Profit Rs 48.49 Cr: this line moved up 28.11% from Rs 37.85 Cr, a larger rise than revenue recorded.
- Net profit margin: the margin improved to 8.1% from 7.1% in the comparison quarter, which is PAT measured against revenue.
- Gufic Biosciences Q2 Results FY27 basis: all figures are Consolidated and compare July to September 2026 with the same quarter in 2025.
- Next step: the performance analysis below shows how the three lines moved against one another.
Gufic Biosciences Q2 Results FY27: Performance Analysis
The performance analysis shows revenue of Rs 288.27 Cr against Rs 237.05 Cr a year earlier, a 21.61% rise. Operating Profit stood at Rs 48.49 Cr, up 28.11%, while net profit was Rs 23.47 Cr, up 39.54%. Together these quarterly results describe a quarter in which all three lines were higher than the year-ago quarter.
Gufic Biosciences Q2 Results FY27 put the revenue change at Rs 51.22 Cr higher, the Operating Profit change at Rs 10.64 Cr higher and the net profit change at Rs 6.65 Cr higher, all measured against the same quarter last year on a Consolidated basis. This results analysis also shows that the percentage rise in net profit is larger than the percentage rise in revenue.
Investors tracking Gufic Biosciences Q2 Results will watch whether YoY growth in revenue continues and whether Operating Profit and net profit keep moving up in later quarters. The percentage rises widen from revenue at 21.61% to Operating Profit at 28.11% and net profit at 39.54%. They can follow later filings through the Univest Screener, which is where the quarterly results turn to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue growth – Revenue grew 21.6% year on year to Rs 288.27 Cr in the latest quarter, the first business factor listed for the company, and Gufic Biosciences Q2 Results FY27 sit alongside it on a Consolidated basis.
Net profit rise – Net profit rose 39.5% year on year to Rs 23.47 Cr, which is the second business factor and reads together with the revenue growth above.
Margin improvement – Net profit margin improved to 8.1% from 7.1% in the comparison quarter, which leads into the results analysis of the outlook.
FY27 Outlook After Gufic Biosciences Q2 Results
A results analysis for FY27 starts from the figures reported so far: revenue of Rs 288.27 Cr and net profit of Rs 23.47 Cr for the July to September 2026 quarter. The remainder of FY27 will depend on subsequent quarters and on conditions disclosed in later filings. The improvement in net profit margin from 7.1% to 8.1% gives a reference point for what later filings may show.
Gufic Biosciences Q2 Results FY27 give one data point for the year on a Consolidated basis, and the comparison between a 21.61% revenue rise and a 39.54% net profit rise is the one to follow as the year moves on, and the Consolidated basis keeps every comparison like for like. That comparison also leads into the key risks.
Key Risks to Watch After Gufic Biosciences Q2 Results FY27
Debt at 0.58 Times Total Assets
Debt was high at 0.58 times total assets in FY26. Gufic Biosciences Q2 Results FY27 show higher net profit, and the debt level is a separate point that investors can follow in later filings.
Return on Equity of 10.14%
Return on equity declined to 10.14% in FY26 from 12.29% in FY25. Investors may track whether the net profit of Rs 23.47 Cr reported in this quarter changes that ratio in later periods, which brings the review to its conclusion.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Gufic Biosciences Q2 Results FY27 show higher revenue, Operating Profit and net profit YoY on a Consolidated basis. The quarterly results and the consolidated results table together give the full picture of a quarter with a 21.61% revenue rise and a 39.54% rise in net profit. Readers of Gufic Biosciences Q2 Results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Gufic Biosciences Q2 Results FY27
What are Gufic Biosciences Q2 Results FY27?
Ans. Gufic Biosciences Q2 Results FY27 are the consolidated results for July to September 2026, with revenue of Rs 288.27 Cr and net profit of Rs 23.47 Cr, as the Quick Answer summarises.
What is the results date for Gufic Biosciences Q2 Results FY27?
Ans. The results date for Gufic Biosciences Q2 Results FY27 is 14 November 2026, which is why the opening paragraphs describe the July to September 2026 quarter on a Consolidated basis.
What revenue was reported in Gufic Biosciences Q2 Results FY27?
Ans. Gufic Biosciences reported revenue of Rs 288.27 Cr for the quarter, compared with Rs 237.05 Cr a year earlier, so the Financial Highlights table shows a 21.61% rise.
What net profit was reported in Gufic Biosciences Q2 Results FY27?
Ans. Gufic Biosciences reported net profit of Rs 23.47 Cr against Rs 16.82 Cr a year earlier, which means PAT rose 39.54% as the Key Takeaways section notes.
How much YoY growth did revenue show in Gufic Biosciences Q2 Results FY27?
Ans. Revenue showed YoY growth of 21.61% in Gufic Biosciences Q2 Results FY27, from Rs 237.05 Cr to Rs 288.27 Cr, while the Performance Analysis puts the absolute change at Rs 51.22 Cr.
Did net profit rise or fall in Gufic Biosciences Q2 Results?
Ans. Net profit rose 39.54% YoY to Rs 23.47 Cr in Gufic Biosciences Q2 Results, compared with Rs 16.82 Cr, so the Performance Analysis section measures the change at Rs 6.65 Cr.
What was the Operating Profit in Gufic Biosciences Q2 Results FY27?
Ans. Operating Profit was Rs 48.49 Cr, up 28.11% from Rs 37.85 Cr, while the Key Takeaways section shows it rose by more than revenue over the same period.
Are Gufic Biosciences Q2 Results consolidated results or standalone results?
Ans. Gufic Biosciences Q2 Results are consolidated results, so every figure in the article is on a Consolidated basis, as the Quick Answer and the Financial Highlights table show.
What business factors shaped Gufic Biosciences Q2 Results FY27?
Ans. The listed business factors are revenue growth of 21.6%, a 39.5% rise in net profit and a net profit margin of 8.1%, as the Key Business Factors section explains.
What are the key risks after Gufic Biosciences Q2 Results FY27?
Ans. The key risks are debt at 0.58 times total assets and return on equity of 10.14% in FY26, down from 12.29% in FY25, as covered under Key Risks to Watch.
What is the outlook after Gufic Biosciences Q2 Results?
Ans. The outlook after Gufic Biosciences Q2 Results rests on subsequent quarters, since the remainder of FY27 depends on later filings, as the FY27 Outlook section explains.
Where can I find the complete Gufic Biosciences Q2 Results FY27 data?
Ans. The complete data sits in the Financial Highlights table above, while the Univest Screener and the Univest app carry wider results date and company details.
